About the MELD Calculator (Model for End-Stage Liver Disease)
The Model for End-Stage Liver Disease (MELD) score is a laboratory-based measure of liver disease severity, built from three routine blood tests: serum bilirubin, INR (international normalized ratio), and serum creatinine. It was originally developed to predict mortality after a transjugular intrahepatic portosystemic shunt (TIPS) procedure, then adopted in 2002 to rank adult candidates on the U.S. liver transplant waiting list. Since January 2016, the sodium-adjusted variant, MELD-Na, has been the primary score used for that ranking.
How the score is calculated
The base score is MELD = 3.78 x ln(bilirubin) + 11.2 x ln(INR) + 9.57 x ln(creatinine) + 6.43. Any bilirubin, INR, or creatinine value below 1.0 is rounded up to 1.0 before the logarithm is taken, and creatinine is capped at 4.0 mg/dL (and set to exactly 4.0 if the patient had two or more dialysis sessions, or 24 hours of continuous veno-venous hemodialysis, in the past week). When the resulting score is above 11, sodium is factored in: MELD-Na = MELD + 1.32 x (137 - Na) - [0.033 x MELD x (137 - Na)], with sodium bounded between 125 and 137 mmol/L beforehand. Both the final MELD and MELD-Na values are rounded to the nearest whole number and bounded between 6 and 40.
Interpreting the result
Higher scores indicate more severe liver dysfunction and a higher published rate of short-term mortality. In the original validation cohort, three-month mortality rose from roughly 2% at scores under 10 to about 20% in the 20s, over 50% in the 30s, and above 70% at 40 or above. These bands describe a study population, not an individual patient, and are provided for context rather than as a personal prognosis.
When to consult a professional
This tool performs the standard MELD and MELD-Na arithmetic for education and record-keeping. It does not diagnose liver disease and does not determine actual waiting-list priority, which also depends on blood type, geography, exception points, and UNOS/OPTN policy. Any decision about liver disease management or transplant listing should be made with a hepatologist or transplant team.